Candesartan as an Adjunctive Treatment for Bipolar Depression

Bipolar Disorder Depression Clinical Trial

Official title:

A Pilot, Proof of Concept, Placebo-controlled Trial of Candesartan as an Adjunctive Treatment for Bipolar Depression

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04430959
• Other study ID #: HSC-MS-19-1046
• Status: Withdrawn
• Phase: Early Phase 1
• Start date: October 1, 2020
• Est. completion date: September 1, 2022

Study information

• Verified date: April 2022
• Source: The University of Texas Health Science Center, Houston
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will assess the safety and tolerability of Candesartan when used in patients with Bipolar Disorder, in addition to their medication treatment.

Description:

Pharmacological options for the treatment of Bipolar disorder (BD) are limited and a large proportion of patients does not show adequate response to treatment, especially in the case of bipolar depression. It has been hypothesized that dysfunctions in the renin-angiotensin system (RAS) may be involved in the pathophysiology of BD. We propose a double-blind, randomized, placebo-controlled, cross-over, proof-of-concept trial to investigate the effects of candesartan, an angiotensin-II receptor antagonist capable to cross the blood-brain barrier, as an adjunctive agent in the treatment of bipolar depression. Bipolar patients on a depressive episode will be randomly assigned to undergo two consecutive 4-week treatment periods with either candesartan (4 mg daily) or placebo in a crossover study. At the beginning of each treatment period, participants will complete a resting-state functional MRI scan, to be performed 1.5 hours after the first dose of the study medication. Subjects will be followed weekly and the Montgomery-Asberg Depression Rating Scale (MADRS) will be adopted as the primary outcome measure. Response will be defined as a decrease equal or higher than 50% in the MADRS score from the time of study entry to the 4th week of each treatment period. Possible associations between changes in brain connectivity (measured through resting state functional MRI) and subsequent response to treatment will also be analyzed.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 1, 2022
• Est. primary completion date: July 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

A diagnosis of BD type I or II, and currently in a depressive episode, based on DSM-5 criteria.

Inclusion criteria:

1. Age 18 to 65 years.

2. A diagnosis of BD type I or II according to DSM-5 criteria, established through the administration of the MINI.

3. Currently in a depressive episode, based on DSM-5 criteria.

4. MADRS >20 at entry in the study.

5. No history of hypertension, diabetes, stroke, liver, kidney, heart disease, bleeding disorders, cancer, hypothyroidism, auto-immune diseases, and any brain disorder (seizure disorder, stroke, dementia, or neurodegenerative diseases), as well as other conditions that could impact patient's safety associated with participation in the study.

6. On therapeutic doses of a mood stabilizing drug (anticonvulsants or atypical antipsychotics, but not lithium) or combinations of medications (including antidepressants, as long as receiving at least one mood stabilizing agent) for at least two weeks.

7. Allowed psychiatric comorbid conditions, such as anxiety disorders, PTSD and past history of substance use (as long as do NOT meet abuse or dependence criteria according to the SCID-I in the past 2 months).

Exclusion criteria:

1. Current use of angiotensin receptor antagonists, angiotensin converting enzyme inhibitors. (ACE inhibitors), or a history of allergies or poor tolerability to those medications

2. Current use of lithium or any other medications that could implicate in potentially dangerous. interactions with candesartan, based on available literature and the investigator's judgement.

3. Pregnancy or current breastfeeding.

4. Acute systemic infections or other acute medical conditions at the time of study entry.

5. Acute suicidal or homicidal ideation or other imminent concerns about safety, based on the investigator's judgement and/or on a score equal or higher than 4 in the item 10 of the MADRS.

6. Family history of hereditary neurologic disorder.

7. Unable to give informed consent for any reason.

8. Floating metallic objects in the body.

9. Positive urine drug screening at the time of study entry.

10. Current or previous diagnosis of intellectual disability, learning disability, or other severe neurodevelopmental disorders.

11. History of traumatic brain injury or head trauma with loss of consciousness for more than 30 minutes.

Related Conditions & MeSH terms

• Bipolar Disorder
• Bipolar Disorder Depression
• Depression
• Depressive Disorder

Intervention

Drug:
• Candesartan
Candesartan 4 mg, tablets, orally, once daily for 4 weeks
• Placebo
Candesartan placebo-matching tablets, orally, once daily for 4 weeks

Locations

Country	Name	City	State
United States	The University of Texas Health Science Center at Houston	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Montgomery-Asberg Depression Rating Scale (MADRS) scores at the end of each treatment period.	MADRS scores range from 0-60; higher scores indicate a higher level of severity of depressive symptoms. Response will be defined as a decrease equal or higher than 50% in the total MADRS score between the baseline and the 4th week of each treatment period.	Four weeks
Secondary	Hamilton Anxiety Rating Scale (HAM-A) scores at the end of each treatment period.	HAM-A scores range from 0-56, with higher scores indicating more severe anxiety	Four weeks
Secondary	Clinical Global Impression - Severity scale (CGI-S) scores at the end of each treatment period.	The CGI-S is a 7-point scale used to rate the severity of the patient's illness at the time of assessment, compared to the clinician's past experience regarding patients with similar diagnosis	Four weeks
Secondary	Functional Assessment Screening Tool scores at the end of each treatment period.	The Functional Assessment Screening Tool (FAST) identifies factors that may influence problem behaviors. It is a self-report checklist that contains 16 items, with each questions being marked as either "yes", "no", or "not applicable". The checklist is designed to identify whether maladaptive behavior is maintained in four domains: attention/preferred items, escape from tasks/activities, sensory stimulation, pain attenuation.	Four weeks
Secondary	Young Mania Rating Scale (YMRS) at the end of each treatment period	The YMRS is one of the most frequently utilized rating scales to assess manic symptoms. The scale has 11 items, based on the patient's subjective report and observations made during the clinical interview. Higher scores indicate a greater severity of manic symptoms. Given the cyclic nature of BD, the YMRS will be utilized to monitor patients as for the possibility of a manic switch over each four-week treatment period.	Four weeks